Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies.

Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, Valle LD, Trillo-Tinoco J, Maj T, Zou W, Rodriguez PC, Ochoa AC.

Cancer Immunol Res. 2015 Nov;3(11):1236-47. doi: 10.1158/2326-6066.CIR-15-0036. Epub 2015 May 29.

2.

Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.

Sawant A, Schafer CC, Jin TH, Zmijewski J, Tse HM, Roth J, Sun Z, Siegal GP, Thannickal VJ, Grant SC, Ponnazhagan S, Deshane JS.

Cancer Res. 2013 Nov 15;73(22):6609-20. doi: 10.1158/0008-5472.CAN-13-0987. Epub 2013 Oct 1.

3.

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.

Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, Umansky V.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17111-6. doi: 10.1073/pnas.1108121108. Epub 2011 Oct 3.

4.

T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy.

Raber PL, Sierra RA, Thevenot PT, Shuzhong Z, Wyczechowska DD, Kumai T, Celis E, Rodriguez PC.

Oncotarget. 2016 Apr 5;7(14):17565-78. doi: 10.18632/oncotarget.8197.

5.

Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.

Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, Pili R.

Cancer Immunol Res. 2015 Feb;3(2):136-48. doi: 10.1158/2326-6066.CIR-14-0036. Epub 2014 Nov 4.

6.

Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy.

Di Mitri D, Toso A, Alimonti A.

Clin Cancer Res. 2015 Jul 15;21(14):3108-12. doi: 10.1158/1078-0432.CCR-14-2261. Epub 2015 May 12. Review.

7.

Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells.

Al-Khami AA, Zheng L, Del Valle L, Hossain F, Wyczechowska D, Zabaleta J, Sanchez MD, Dean MJ, Rodriguez PC, Ochoa AC.

Oncoimmunology. 2017 Jun 30;6(10):e1344804. doi: 10.1080/2162402X.2017.1344804. eCollection 2017.

8.

Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2.

Beury DW, Carter KA, Nelson C, Sinha P, Hanson E, Nyandjo M, Fitzgerald PJ, Majeed A, Wali N, Ostrand-Rosenberg S.

J Immunol. 2016 Apr 15;196(8):3470-8. doi: 10.4049/jimmunol.1501785. Epub 2016 Mar 2.

9.

Myeloid suppressor cell depletion augments antitumor activity in lung cancer.

Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, Sharma S.

PLoS One. 2012;7(7):e40677. doi: 10.1371/journal.pone.0040677. Epub 2012 Jul 16. Erratum in: PLoS One. 2012;7(10). doi:10.1371/annotation/5c756e7d-6e97-416f-836a-dced97cf46af. Kar, Upendra [corrected to Kar, Upendra K].

10.

Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.

Mikyšková R, Indrová M, Polláková V, Bieblová J, Símová J, Reiniš M.

J Immunother. 2012 Jun;35(5):374-84. doi: 10.1097/CJI.0b013e318255585a.

PMID:
22576342
11.

TNF Receptor-2 Facilitates an Immunosuppressive Microenvironment in the Liver to Promote the Colonization and Growth of Hepatic Metastases.

Ham B, Wang N, D'Costa Z, Fernandez MC, Bourdeau F, Auguste P, Illemann M, Eefsen RL, Høyer-Hansen G, Vainer B, Evrard M, Gao ZH, Brodt P.

Cancer Res. 2015 Dec 15;75(24):5235-47. doi: 10.1158/0008-5472.CAN-14-3173. Epub 2015 Oct 19.

12.

Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.

Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.

Cancer Res. 2014 Jan 1;74(1):104-18. doi: 10.1158/0008-5472.CAN-13-1545. Epub 2013 Nov 6.

13.

Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.

Nonaka K, Saio M, Suwa T, Frey AB, Umemura N, Imai H, Ouyang GF, Osada S, Balazs M, Adany R, Kawaguchi Y, Yoshida K, Takami T.

J Leukoc Biol. 2008 Sep;84(3):679-88. doi: 10.1189/jlb.1107729. Epub 2008 Jun 19.

PMID:
18566103
14.

Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.

Gobbo J, Marcion G, Cordonnier M, Dias AMM, Pernet N, Hammann A, Richaud S, Mjahed H, Isambert N, Clausse V, Rébé C, Bertaut A, Goussot V, Lirussi F, Ghiringhelli F, de Thonel A, Fumoleau P, Seigneuric R, Garrido C.

J Natl Cancer Inst. 2015 Nov 22;108(3). doi: 10.1093/jnci/djv330. Print 2016 Mar.

PMID:
26598503
15.

PI3Kγ Activates Integrin α4 and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression.

Foubert P, Kaneda MM, Varner JA.

Cancer Immunol Res. 2017 Nov;5(11):957-968. doi: 10.1158/2326-6066.CIR-17-0143. Epub 2017 Sep 28.

16.

Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.

Zhong H, Gutkin DW, Han B, Ma Y, Keskinov AA, Shurin MR, Shurin GV.

Int J Cancer. 2014 Jun 1;134(11):2633-45. doi: 10.1002/ijc.28590. Epub 2014 Jan 20.

17.

Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.

Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, Gillanders WE, Linehan DC, Goedegebuure P.

Cancer Immunol Immunother. 2012 Sep;61(9):1373-85. doi: 10.1007/s00262-011-1178-0. Epub 2012 Jan 4.

18.

Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.

Shi S, Wang R, Chen Y, Song H, Chen L, Huang G.

PLoS One. 2013 Jun 14;8(6):e65757. doi: 10.1371/journal.pone.0065757. Print 2013.

19.

CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.

Zoglmeier C, Bauer H, Noerenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C.

Clin Cancer Res. 2011 Apr 1;17(7):1765-75. doi: 10.1158/1078-0432.CCR-10-2672. Epub 2011 Jan 13. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1117.

20.

Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression.

Tsukamoto H, Nishikata R, Senju S, Nishimura Y.

Cancer Immunol Res. 2013 Jul;1(1):64-76. doi: 10.1158/2326-6066.CIR-13-0030. Epub 2013 Apr 29.

Supplemental Content

Support Center